Regulation of the renin–angiotensin system in coronary atherosclerosis: A review of the literature

References

• [ALLHAT] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• Al-MallahMTleyjehIAbdel-LatifAAngiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic functionJ Am Coll Cardiol20064715768316630993
   PubMed Web of Science ®Google Scholar
• AndersenSSchalkwijkCGStehouwerCDAngiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathyDiabetes Care2000231031210895868
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRMacMahonSBlood pressure stroke and coronary heart disease. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological contextLancet1990335827381969567
   PubMed Web of Science ®Google Scholar
• CushmanDWWangFLFungWCDifferentiation of angiotensin converting enzyme inhibitors (ACE) by their selective inhibition of ACE in physiologically important target organsAm J Hypertens198922943062706094
   PubMed Web of Science ®Google Scholar
• CusiKMaezonoKOsmanAInsulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscleJ Clin Invest20001053112010675357
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• [DREAM] The DREAM (Diabetes reduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsEffect of ramipril on the incidence of diabetesN Engl J Med200635515516216980380
   PubMed Web of Science ®Google Scholar
• FisherNHollenbergNRenin inhibition: What are the therapeutic opportunities?J Am Soc Nephro2005165929
   PubMed Web of Science ®Google Scholar
• FoxKMEuropean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease InvestigatorsEfficacy on perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362782813678872
   PubMed Web of Science ®Google Scholar
• FrankenAAMDerkxFHMMan in’t VeldAJHigh plasma prorenin in diabetes mellitus and its correlation with some complicationsJ Clin Endocrinol Metab1990711008152205621
   PubMed Web of Science ®Google Scholar
• FuruhashiMUraNHigashiuraKBlockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients with Essential HypertensionHypertension200342768112796280
   PubMed Web of Science ®Google Scholar
• GriendlingKKMinieriCAOllerenshawJDAngiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cellsCirc Res199474114188187280
   PubMed Web of Science ®Google Scholar
• GriendlingKKSorescuDUshio-FukaiMNAD(P)H oxidase: role in cardiovascular biology and diseaseCirc Res20008649450110720409
   PubMed Web of Science ®Google Scholar
• GuayDRTrandolapril: a newer angiotensin-converting enzyme inhibitorClin Ther2003257137512852701
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHNiskanenLEffect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trialLancet19993536111610030325
   PubMed Web of Science ®Google Scholar
• [HOPE] The Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trialLancet200336320223115207952
   PubMed Web of Science ®Google Scholar
• KhanBVSolaSLautenWQuinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndromeDiabetes Care20042717121515220251
   PubMed Web of Science ®Google Scholar
• KøberLTorp-PedersenCCarlsenJEA clinical trial of the angiotensin-converting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med1995333167067477219
   PubMed Web of Science ®Google Scholar
• KondoJSoneTSuboiHEffects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery diseaseAm Heart J200314610227
   Web of Science ®Google Scholar
• KonVJabsKAngiotensin in atherosclerosisCurr Opin Nephrol Hypertens200413291715073487
   PubMed Web of Science ®Google Scholar
• KrutzfeldtJRaaschWKleinHHRamipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive ratsNaunyn Schmiedebergs Arch Pharmacol20003621610935526
   PubMed Web of Science ®Google Scholar
• LakkaHMLaaksonenDELakkaTAThe metabolic syndrome and total and cardiovascular disease mortality in middle-aged menJAMA200228827091612460094
   PubMed Web of Science ®Google Scholar
• LauDCDhillonBYanHAdipokines: molecular links between obesity and atherosclerosisAm J Physiol Heart Circ Physiol2005288H20314115653761
   PubMed Web of Science ®Google Scholar
• LindholmLHIbsenHDahlöfBCardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenololLancet200235910041011937179
   PubMed Web of Science ®Google Scholar
• LonnEWeitzJDzavikVfor the SECURE and HOPE InvestigatorsEffects of ramipril and vitamin E on hematological markers of fibrinolysis, coagulation and endothelial function: results of the MORE-HOPE studyCan J Cardiol200016Suppl F233F
   Google Scholar
• MacMahonSSharpeNGambleGRandomized, placebo-controlled trial of the angiotensin–converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial diseaseJ Am Coll Cardiol2000364384310933355
   PubMed Web of Science ®Google Scholar
• ManciniGBJHenryGCMacayaCAngiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) StudyCirculation199694258658759064
   PubMed Web of Science ®Google Scholar
• MiyazakiMKawamotoTOkunishiHVascular affinity of trandolaprilAm J Hypertension1995863S67S
   PubMed Web of Science ®Google Scholar
• MontagnaniMGolovchenkoIKimIInhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cellsJ Biol Chem20022771794911707433
   PubMed Web of Science ®Google Scholar
• NagamiaSPandianACheemaFThe role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndromePrev Cardiol2007In press
   PubMedGoogle Scholar
• NissenSTuzcuMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA200429222172515536108
   PubMed Web of Science ®Google Scholar
• NussbergerJWuerznerGJensenCAngiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalaprilHypertension20023918
   PubMed Web of Science ®Google Scholar
• OrtleppJRBreuerJEitnerFInhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemiaEur J Pharmacol20024361455011834258
   PubMed Web of Science ®Google Scholar
• [PEACE] The PEACE Trial InvestigatorsAngiotensin-converting-enzyme inhibition in stable coronary artery diseaseN Engl J Med200435205868
   Google Scholar
• PfefferMABraunwaldEMoyeLAfor the SAVE InvestigatorsEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement TrialN Engl J Med1992327669771386652
   PubMed Web of Science ®Google Scholar
• PfefferMMcMurrayJVelazquezEValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349189390614610160
   PubMed Web of Science ®Google Scholar
• PfefferMSwedbergKGrangerCEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programLancet20033627596613678868
   PubMed Web of Science ®Google Scholar
• PischonTGirmanCJHotamisligilGSPlasma adiponectin levels and risk of myocardial infarction in menJAMA20042911730715082700
   PubMed Web of Science ®Google Scholar
• PittBACE inhibitors for patients with vascular disease without left ventricular dysfunction-may they rest in peace?N Engl J Med200435121151715531768
   PubMed Web of Science ®Google Scholar
• PittBO’NeillBFeldmanRThe Quinapril Ischemic Event Trial (QUIET) evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular functionAm J Cardiol20018710586311348602
   PubMed Web of Science ®Google Scholar
• PollareTLithellHBerneCA comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertensionN Engl J Med1989321868732671740
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens200720112017198906
   PubMed Web of Science ®Google Scholar
• PrasadAKohKKSchenkeWHRole of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosisAm Heart J20011422485311479463
   PubMed Web of Science ®Google Scholar
• PrasadAQuyyumiARenin-angiotensin system and angiotensin receptor blockers in the metabolic syndromeCirculation200411015071215364819
   PubMed Web of Science ®Google Scholar
• RajagopalanSKurzSMünzelTAngiotensin II–mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activationJ Clin Invest1996971916238621776
   PubMed Web of Science ®Google Scholar
• SchmidtAMYanSDWautierJLActivation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosisCirc Res1999844899710082470
   PubMed Web of Science ®Google Scholar
• ShiuchiTCuiTXWuLACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NOHypertension2002403293412215475
   PubMed Web of Science ®Google Scholar
• SkeggLTKhanJRLentzKEPreparation, purification, and amino acid sequence of a polypeptide renin substrateJ Exp Med19571064395313463253
   PubMed Web of Science ®Google Scholar
• StantonAJensenCNussbergerJBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension20034211374314597641
   PubMed Web of Science ®Google Scholar
• SzmitkoPWangCHWeiselRDBiomarkers of vascular disease linking inflammation to endothelial activationCirculation20031082041814581382
   PubMed Web of Science ®Google Scholar
• TanKChowWWongYEffect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuriaDiabetes Care200225125412087039
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med1992327685911463530
   PubMed Web of Science ®Google Scholar
• TsikourisJPCoxDCPharmacologic blockade of the renin angiotensin system: vascular benefits beyond commonly understood pharmacologic actionsPharmacotherapy20032311415214524646
   PubMed Web of Science ®Google Scholar
• VellosoLAFolliFSunXJCross-talk between the insulin and angiotensin signaling systemsProc Natl Acad Sci USA1996931249058901609
   PubMed Web of Science ®Google Scholar
• WagnerAHKohlerTRuckschlossUImprovement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formationArterioscler Thromb Vasc Biol20002061910634801
   PubMed Web of Science ®Google Scholar
• YusufSFrom the HOPE to the ONTARGET and TRANSCEND studies: challenges in improving prognosisAm J Cardiol20028918A26A11779516
   PubMed Web of Science ®Google Scholar
• YusufSGersteinHHoogwerfBRamipril and the development of diabetesJAMA20012861882511597291
   PubMed Web of Science ®Google Scholar